安旭生物(688075) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥196,648,169.86, representing a year-over-year increase of 4.62%[5] - The net profit attributable to shareholders for Q3 2022 reached ¥254,666,293.91, a significant increase of 211.38% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,696,376.94, up 209.48% year-over-year[5] - Total operating revenue for the first three quarters of 2022 reached CNY 6,126,614,488.82, a significant increase from CNY 681,989,024.08 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was CNY 3,131,740,429.19, a substantial rise from CNY 283,904,582.25 in 2021[21] - The company reported a total comprehensive income of CNY 3,183,109,146.63 for the third quarter of 2022, up from CNY 284,351,161.66 in the same quarter of 2021[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,608,601,462.05, reflecting a 131.94% increase from the end of the previous year[6] - The company's total liabilities reached CNY 2,060,066,724.14, while total equity was CNY 5,548,534,737.91[19] - The company’s total assets amounted to approximately ¥7.61 billion, compared to ¥3.28 billion at the end of 2021[17] - The company’s inventory increased to approximately ¥429.39 million from ¥243.35 million year-over-year[17] - The company’s fixed assets were valued at approximately ¥477.78 million, up from ¥139.24 million[17] - The company’s total liabilities included short-term borrowings of ¥2 million and accounts payable of approximately ¥1.64 billion[17] Research and Development - Research and development expenses for Q3 2022 amounted to ¥36,541,930.24, a 224.74% increase compared to the same period last year[6] - The R&D expenses accounted for 18.58% of operating revenue, an increase of 12.58 percentage points year-over-year[6] - Research and development expenses for the first three quarters of 2022 totaled CNY 690,730,825.03, compared to CNY 30,337,987.15 in the same period last year[20] Earnings Per Share - The basic earnings per share for Q3 2022 were ¥2.81, up 57.87% from the previous year[6] - The diluted earnings per share for Q3 2022 were also ¥2.81, reflecting a 57.87% increase year-over-year[6] - Basic and diluted earnings per share for the third quarter of 2022 were CNY 34.51, compared to CNY 6.17 in the previous year[22] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥3,935,709,712.99, representing a 1,102.68% increase compared to the same period last year[6] - The cash inflow from operating activities for the first three quarters of 2022 reached ¥6,587,653,959.61, a significant increase from ¥806,134,255.58 in the same period of 2021, representing an increase of approximately 717%[24] - The net cash flow from operating activities was ¥3,935,709,712.99, compared to ¥327,246,097.36 in the previous year, indicating a growth of about 1,103%[24] - The cash inflow from investment activities totaled ¥5,955,062,284.83, up from ¥24,044,618.19 in 2021, marking an increase of approximately 24,757%[25] - The net cash flow from investment activities was -¥3,038,153,230.16, compared to -¥240,821,387.22 in the same period last year, reflecting a deterioration in investment cash flow[25] - The cash inflow from financing activities was ¥300,000.00, while the cash outflow totaled ¥240,701,565.59, resulting in a net cash flow of -¥240,401,565.59[25] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 10,118[13] - The top shareholder, Hangzhou Aixi Holdings, holds 26.87% of the shares, followed by Ling Shisheng with 25.12%[14] Future Plans - The company plans to expand its market presence and invest in new product development[15] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[23] Dividend Distribution - The company has implemented a dividend distribution of ¥3.88 per share and a capital reserve increase of 0.48 shares for every share held[15]